Biote to Become Public Company through Business Combination with Special Purpose Acquisition Company Haymaker III (Nasdaq: HYAC)

This transaction will provide the financing to accelerate our strategic growth program, bringing hormone replacement therapy to an overlooked market. Upon completion of the business combination, Biote will trade on the Nasdaq Stock Exchange under the ticker BTMD.



Read more about Biote becoming a public company through the business combination with Haymaker Acquisition Corp. III and what it means for the future of Biote.


To learn more about this transformational event, please watch the official presentation at the link below.

For more information, please reach out to:

Media Contact

Sean Leous
[email protected]

Investor Contact

Mike Cavanaugh
[email protected]


Biote is a hormone optimization company that has translated over 80 years of scientific insight into clinically-validated medical approaches that identify and treat imbalances in the production of hormones. By partnering with over 4,700 medical providers across the United States, Biote is educating practitioners on the scientific evidence of the roles of hormones and supplements to support improved health, and on responsible treatment of patients. We are dedicated to helping patients live better, longer by changing the way healthcare is practiced on a global level.